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A B S T R A C T
The increasing prevalence of multidrug-resistant (MDR) Klebsiella pneumoniae is a serious clinical
and public health problem, and colistin is the last-resort treatment option for MDR infections. However,
resistance to colistin has been increasingly reported in the world, such as the Middle East region, where
antibiotics are used more in the human and agriculture industry. In this paper, we review the available
data on the molecular mechanisms and prevalence of colistin resistance of K. pneumoniae in the Middle
East over the last 5 years. To the best of our knowledge, 590 colistin-resistant K. pneumoniae isolates
were reported from six countries, including Turkey (438), Iran (86), Saudi Arabia (24), United Arab
Emirates (31), Kuwait (5), Israel (3) and Lebanon (3), between 2013 and 2018. However, there has been no
reports about colistin resistance among K. pneumoniae isolates in Iraq, Yemen, Syria, Jordan, Palestine,
Oman, Qatar, Bahrain and Cyprus. Moreover, it seems that mutations and insertion sequence
transpositions in the mgrB gene were the most common colistin resistance mechanisms among K.
pneumoniae in the Middle East region, which is similar to other parts of the world.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Klebsiella pneumoniae is a member of ESKAPE pathogens, which
are the leading cause of nosocomial infections worldwide, and they for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-
